Financial Performance - The company's operating revenue for Q1 2024 was ¥19,624,282,945.17, a slight increase of 0.02% compared to ¥19,620,276,794.03 in the same period last year[31]. - The net profit attributable to shareholders decreased by 37.99% to ¥102,960,760.48 from ¥166,044,332.35 year-on-year[31]. - The company's total revenue for the first quarter was CNY 19.62 billion, showing a marginal increase of 0.02% compared to CNY 19.62 billion in the previous year[55]. - Net profit for the first quarter was ¥134,762,927.50, down 41.9% from ¥231,764,045.24 in the same period last year[66]. - The company reported a decrease in operating profit to ¥173,133,845.71, down 37.2% from ¥275,798,806.94 year-over-year[66]. - The company’s total comprehensive income for the period was ¥134,762,927.50, down 41.9% from ¥231,764,045.24 in the previous year[66]. - Basic and diluted earnings per share both decreased to ¥0.06 from ¥0.10[72]. Cash Flow - The net cash flow from operating activities showed a net outflow increase of 1.86%, amounting to -¥3,151,359,275.90 compared to -¥3,093,724,213.10 in the previous year[31]. - The company's cash inflow from operating activities for the first quarter was approximately CNY 20.60 billion, an increase from CNY 18.15 billion in the previous year, representing a growth of 13.5%[47]. - The net cash flow from operating activities was a negative CNY 3.15 billion, slightly worse than the negative CNY 3.09 billion recorded in the same period last year, indicating an increase in cash outflow by 1.86%[58]. - The company’s cash flow from financing activities showed a net outflow of ¥416,716,243.92, contrasting with a net inflow of ¥1,330,850,572.46 in the prior year[68]. Assets and Liabilities - The total assets at the end of the reporting period were ¥64,823,403,035.93, reflecting a 2.05% increase from ¥63,523,679,581.87 at the end of the previous year[31]. - Total assets increased to ¥55,807,192,032.72 from ¥54,576,699,681.65, reflecting a growth of approximately 2.25%[64]. - The total liabilities increased to ¥54,313,049,202.80, indicating a rise of approximately 3.5% from the previous period[64]. - Total liabilities rose to ¥49,185,299,480.36 from ¥48,016,315,030.77[70]. - Non-current liabilities increased significantly to ¥6,920,537,273.36 from ¥5,155,886,955.29[70]. Receivables and Inventory - Accounts receivable increased by 7.79% to ¥35,463,920,220.33 from ¥32,900,523,781.08 at the beginning of the year[33]. - Accounts receivable rose to ¥35,463,920,220.33, an increase of 7.8% compared to ¥32,900,523,781.08 at the beginning of the period[64]. - Inventory rose by 4.94% to ¥8,315,792,092.61 compared to ¥7,924,619,690.16 at the beginning of the year[33]. - The company’s inventory increased to ¥8,315,792,092.61, up 4.9% from ¥7,924,619,690.16 at the beginning of the period[64]. Expenses - Financial expenses decreased by 21.51% due to a reduction in total interest-bearing liabilities and financing costs[35]. - Management expenses rose by 16.20% year-on-year, attributed to increased labor costs and depreciation expenses[55]. - Total operating costs increased to ¥19,384,577,382.40 from ¥19,279,821,546.58, with operating costs specifically rising from ¥17,995,584,878.72 to ¥18,103,470,070.75[71]. - Research and development expenses decreased significantly to ¥199,371.05 from ¥1,497,098.60[71]. - Financial expenses decreased to ¥257,833,703.68 from ¥328,473,998.37, with interest expenses dropping from ¥343,628,880.39 to ¥272,482,546.01[71]. Investment - Investment income increased by 24.72% year-on-year, reaching CNY 86.72 million, primarily due to profits from joint ventures[57]. - Investment income increased to ¥86,719,317.32 from ¥69,531,348.46, primarily from joint ventures and associates[71]. - The cash outflow from investment activities was significantly reduced by 233.9%, indicating a shift in investment strategy[58]. - The total cash inflow from investment activities was CNY 17.69 million, down from CNY 109.70 million in the previous year, reflecting a strategic shift in investment focus[58]. Strategic Focus - The company is focusing on digital transformation and expanding its business scope to adapt to changing market demands[8]. - The company received government subsidies amounting to CNY 9.01 million, contributing positively to its financial performance[52].

重药控股股份有限公司 2023年度董事会工作报告 2023年，重药控股股份有限公司（以下简称"公司"、"重药控股"）董事会严格 按照《公司法》、《证券法》、《上市公司治理准则》、《深圳证券交易所股票上 市规则》、《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运 作》等国家法律、法规及《公司章程》、《董事会议事规则》等规定，本着对全体 股东负责的态度，恪尽职守、积极有效地行使职权，认真贯彻落实股东大会的各项 决议，勤勉尽责地开展董事会各项工作，推动公司治理水平的提高和公司各项业务 发展。现将2023年度董事会工作情况报告如下： 一、2023年经营情况 报告期内，公司实现营业收入801.19亿元，同比增长18.12%；实现归属于上市 公司股东的净利润6.55亿元，同比下降31.22%；实现归属于上市公司股东扣除非经 常性损益后净利润为5.83亿元，同比下降33.45%。实现每股收益0.38元/股，扣除非 经常性损益每股收益0.34元/股。截至2023年12月31日，公司资产总额为635.24亿元， 所有者权益为155.07亿元，扣除少数股东权益后所有者权益为112.46亿元。 二、2023年董事会 ...

重药控股股份有限公司独立董事 2023 年度述职报告 重药控股股份有限公司 2023 年度独立董事述职报告 龚涛（已离任） 根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所上市公司 自律监管指引第 1 号—主板上市公司规范运作》等相关法律法规和《公司章程》、 公司《独立董事管理办法》的规定与要求，本人自担任重药控股股份有限公司（以 下简称"公司"）独立董事以来，恪尽职守、勤勉尽责，积极出席相关会议，认真 审议董事会各项议案，全面关注公司的发展状况，切实维护了公司和股东，尤其 是中小股东的利益。现将 2023 年度本人履行独立董事职责的情况汇报如下： 二、2023 年度履职概况 （一）出席股东大会及董事会情况 报告期内本人任职期间，作为公司独立董事，本人均按时出席相关会议，认 真讨论并审议各项议案，与公司管理层进行充分沟通，并结合自身专业领域提出 1 重药控股股份有限公司独立董事 2023 年度述职报告 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人龚涛，男，1969 年 5 月生，中国国籍，博士研究生、教授。现任四川 大学华西药学院教授、天津红日药业股份有限公司、重庆智飞生物科技股份有限 ...

证券代码：000950 证券简称：重药控股 公告编号：2024-028 重药控股股份有限公司 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 重药控股股份有限公司（以下简称"公司"）第九届董事会第五次会议于 2024年4月25日在公司会议室以现场与通讯表决相结合的形式召开，会议通知于 2024年4月15日以电子邮件和电话通知方式发出。会议应出席董事11人，实际出 席会议的董事11人。会议由公司董事长袁泉主持。本次会议的召开符合《公司法》、 《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《2023年度总经理工作报告》 表决结果：同意11票，反对0票，弃权0票。 （二）审议通过《2023年度董事会工作报告》 董事会审议了《2023年度董事会工作报告》，同时公司独立董事分别向董事 会提交了《2023年度独立董事述职报告》，并将在公司2023年度股东大会上述职。 董事会根据现任独立董事提交的2023年度独立性情况自查报告，出具了《董 事会关于独立董事独立性自查情况的专项意见》。 表决结果：同意1 ...

证券代码：000950 证券简称：重药控股 公告编号：2024-030 重药控股股份有限公司 第八届监事会第二十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 重药控股股份有限公司（以下简称"公司"）第八届监事会第二十五次会议于 2024年4月25日在公司会议室以现场与通讯表决相结合的形式召开，会议通知于 2024年4月15日以电子邮件和电话通知方式发出。会议应出席监事4人，实际出席 会议的监事4人，会议推选职工监事吕雪莹作为本次会议的主持人。本次会议的 召开符合《公司法》《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议通过《2023年度总经理工作报告》 表决结果：同意 4 票，反对 0 票，弃权 0 票。 （二）审议通过《2023年度监事会工作报告》 具体内容详见同日披露的《2023 年度监事会工作报告》。 表决结果：同意 4 票，反对 0 票，弃权 0 票。 本议案尚需提交股东大会审议。 （三）审议通过《2023年度总法律顾问述职报告》 表决结果：同意 4 票，反对 0 票，弃权 0 票。 （四）审议通 ...

天职国际会计师事务所（特殊普通合伙）（以下简称"天职国际"）创立于 1988 年 12 月，总部北京，是一家专注于审计鉴证、资本市场服务、管理咨询、 政务咨询、税务服务、法务与清算、信息技术咨询、工程咨询、企业估值的特大 型综合性咨询机构。 证券代码：000950 证券简称：重药控股 公告编号：2024-034 重药控股股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.拟续聘的会计师事务所名称：天职国际会计师事务所（特殊普通合伙）。 2.公司本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国 有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 一、拟续聘会计师事务所的基本情况 （一）机构信息 1.基本信息 天职国际首席合伙人为邱靖之，注册地址为北京市海淀区车公庄西路 19 号 68 号楼 A-1 和 A-5 区域，组织形式为特殊普通合伙。 天职国际已取得北京市财政局颁发的执业证书，是中国首批获得证券期货相 关业务资格，获准从事特大型国有企业审计业务资格，取得金融审 ...

重药控股股份有限公司独立董事 2023 年度述职报告 重药控股股份有限公司 2023 年度独立董事述职报告 章新蓉（已离任） 本人于 2021 年 11 月 29 日起担任重药控股股份有限公司（以下简称"公司"） 第八届董事会独立董事，作为公司独立董事，2023 年严格按照《公司法》《上 市公司治理准则》和《深圳证券交易所股票上市规则》等有关法律法规，以及《公 司章程》《独立董事管理办法》等规章制度的规定和要求，以关注和维护全体股 东特别是中小股东的利益为宗旨，恪尽职守、勤勉尽责地行使所赋予的权利，出 席了 2023 年的董事会及其下属专门委员会的相关会议，对公司的经营管理及业 务发展提出积极的建议，充分发挥独立董事作用，对公司规范运作、稳定健康地 发展起到积极的推动作用。现将 2023 年度本人任期内履行独立董事职责情况述 职如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人章新蓉，女，1959 年出生，中国国籍，大学学历。重庆工商大学会计 学院教授，硕士生导师，兼任中国商业会计学会常务理事、重庆市审计学会副会 长、重庆市会计学会常务理事，四川浩物机电股份有限公司、恒大人寿保险有限 公司独立董 ...

Dividend Distribution - The company plans to distribute a cash dividend of 0.5 yuan per 10 shares to all shareholders, based on a total of 1,728,184,696 shares[4]. - The proposed cash dividend is 0.5 CNY per 10 shares, totaling 86,409,234.80 CNY, which represents 100% of the distributable profit[180]. - The total number of shares for the dividend distribution is 1,728,184,696 shares[179]. Business Focus and Restructuring - The company has undergone significant asset restructuring, changing its main business focus to pharmaceutical research and sales, health management, and hospital management since 2017[22]. - The company reported a major shareholder change in 2019, with the controlling shareholder becoming Chongqing Pharmaceutical Health Industry Co., Ltd.[22]. - The company is focusing on internal reforms to improve operational efficiency and market competitiveness, including optimizing its equity structure and promoting mixed-ownership reform[116]. Financial Performance - The company's operating revenue for 2023 was ¥80,119,107,345.07, representing an increase of 18.12% compared to ¥67,829,010,438.13 in 2022[23]. - The net profit attributable to shareholders for 2023 was ¥654,956,871.96, a decrease of 31.22% from ¥952,275,637.06 in 2022[23]. - Basic earnings per share for 2023 were ¥0.38, down 30.91% from ¥0.55 in 2022[23]. - The company achieved a total revenue of ¥80,119,107,345.07 in 2023, representing an 18.12% increase compared to ¥67,829,010,438.13 in 2022[75]. - The company reported a net profit of approximately 761.57 million yuan from its subsidiary Chongqing Medical[110]. Cash Flow and Assets - The net cash flow from operating activities increased by 77.92% to ¥508,534,274.82 in 2023, up from ¥285,828,791.55 in 2022[23]. - The company experienced a negative cash flow from operating activities in the first quarter of 2023, amounting to -¥3,093,724,213.10[27]. - As of the end of 2023, cash and cash equivalents increased to ¥9,148,807,999.03, representing 14.40% of total assets, up from 12.98% at the beginning of the year, a change of 1.42%[93]. - Accounts receivable rose to ¥32,900,523,781.08, accounting for 51.79% of total assets, an increase of 1.99% from 49.80% at the start of the year, primarily due to increased sales revenue[93]. Market and Industry Trends - In 2023, China's GDP surpassed 126 trillion yuan, with a year-on-year growth of 5.2%, and per capita healthcare spending increased by 16%[34]. - The pharmaceutical industry sales scale grew from 1.9 trillion yuan in 2021 to 2.1 trillion yuan in 2022, indicating a steady annual increase[34]. - The implementation of national and provincial centralized procurement policies has led to a noticeable decline in gross margins for pharmaceutical distribution companies[34]. - The healthcare sector is facing pressures from tightening industry policies and the need for compliance, leading to a trend of micro-profitability[34]. Research and Development - The company has over 10 ongoing research projects focused on cardiovascular, neurological, digestive, and autoimmune diseases, with the first MAH product, Olmesartan Medoxomil Tablets, approved and commercialized[74]. - The company is focusing on developing innovative drugs with clinical value and proprietary intellectual property, particularly in biopharmaceuticals and special medical foods[74]. - Research and development (R&D) investment totaled ¥67,747,500.00, a slight decrease of 0.49% compared to the previous year, with a capitalization rate of 33.21%[87]. Digital Transformation and E-commerce - The company emphasizes digital transformation, investing in various information systems to enhance operational efficiency and service capabilities[48]. - The e-commerce platform, 重药云商, recorded a transaction volume exceeding 1.5 billion yuan, reflecting a 52% increase year-on-year[57]. - The company is expanding its e-commerce business and enhancing digital capabilities, aiming to increase the online resource variety on its B2B platform and improve service efficiency[120]. Governance and Management - The company has established a comprehensive governance structure with a board of 11 directors, including 4 independent directors, and a supervisory board of 4 members[129]. - The company is focused on maintaining a robust corporate governance structure to protect shareholder rights[167]. - The independent directors did not receive any compensation during the reporting period, reflecting a commitment to governance[162]. Employee Management - The total number of employees at the end of the reporting period is 14,485, with 62 at the parent company and 14,423 at major subsidiaries[172]. - The employee compensation system includes a tiered salary structure combined with performance assessments, ensuring timely and full payment of salaries[174]. - The company has established a wide-ranging compensation system that includes annual salary and performance-based incentives[174]. Strategic Acquisitions and Investments - The company completed significant equity investments, including a 51% acquisition of Tianjin Wanggui Pharmaceutical for CNY 12.99 million, with an expected return of 8.19%[100]. - The company is focusing on long-term investments in the pharmaceutical sector, with multiple acquisitions aimed at market expansion[100]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product portfolio[140]. Social Responsibility - The company has actively participated in social responsibility initiatives, contributing a total of 40,700 yuan towards consumption poverty alleviation in areas such as Wuxi and Fengdu in 2023[198]. - The company’s main business focuses on pharmaceutical and medical device wholesale and retail, and it is not classified as a key pollutant discharge unit[197].

重 药 控 股 股 份 有 限 公 司 2023 年度涉及财务公司关联交易的存款、 贷款等金融业务的专项说明 天职业字[2024]30432-2 号 关于重药控股股份有限公司 目 录 2023 年度涉及财务公司关联交易的存款、贷款等金融业务的专项说 --- -1 情况汇总表 -- -2 2023 年度涉及财务公司关联交易的存款、贷款等金融业务的专项说明 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.sov.cn）"讲 报告编码:京24 按照中国证监会、中国银保监会《关于规范上市公司与企业集团财务公司业务往来的通知》 以及《深圳证券交易所上市公司自律监管指引第7号 -- 交易与关联交易(2023年修订)》的 要求,贵公司管理层编制了本专项说明所附的《重药控股股份有限公司 2023 年度涉及重庆化 医控股集团财务有限公司关联交易的存款、贷款等金融业务情况汇总表》(以下简称")汇总表")。 如实编制和对外披露汇总表,并确保其真实性、合法性及完整性是贵公司管理层的责任。 我们对汇总表所载资料与我们审计贵公司 2023 年度财务报表时所复核的财务资料和经审计的 财务报表的相关内 ...

重药控股股份有限公司 2023 年度会计师事务所履职情况评估报告 重药控股股份有限公司（以下简称"公司"）聘请天职国际会计师事务所（特 殊普通合伙）（以下简称"天职国际"）作为公司 2023 年度财务报告与内部控制审 计机构。根据财政部、国务院国资委及中国证监会颁布的《国有企业、上市公司 选聘会计师事务所管理办法》，公司对天职国际 2023 年度年审过程中的履职情况 进行评估。经评估，公司认为天职国际资质等方面合规有效，履职保持独立性， 勤勉尽责，公允表达意见。具体情况如下： 一、资质条件 名称：天职国际会计师事务所（特殊普通合伙） 成立日期：1988 年 12 月 组织形式：特殊普通合伙企业 注册地址：北京市海淀区车公庄西路 19 号 68 号楼 A-1 和 A-5 区域 签字注册会计师 2：刘宗磊，2014 年成为注册会计师，2010 年开始从事上 市公司审计，2019 年开始在本所执业，2022 年开始为本公司提供审计服务，近 三年（2021 年度、2022 年度、2023 年度、2024 年初至本公告日止，下同）签署 上市公司审计报告 6 家，近三年复核上市公司审计报告 1 家。 项目质量控制复核人： ...